Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain. Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study.

AbbVie is also currently conducting a Phase II study of elagolix for uterine fibroids to assess blood loss in women with heavy uterine bleeding due to such fibroids. AbbVie expects a Phase IIb study in uterine fibroids to commence in 2013.

VMAT2 UpdateThe Company is currently conducting two Phase IIb studies of its VMAT2 inhibitor NBI-98854.

The Kinect Study is a 120 subject, placebo-controlled, double-blind, parallel design, multiple dose, 12-week study assessing six-week dosing of NBI-98854 against placebo, followed by six weeks of open-label treatment with NBI-98854. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the first six weeks of dosing. The study will also incorporate a capsule formulation of NBI-98854. Top-line data from the placebo-controlled portion of this study is expected in the second quarter of 2013.

The Kinect 2 Study is a 90 subject, placebo-controlled, double-blind, parallel design, multiple dose, six-week study assessing NBI-98854 against placebo. The primary endpoint is the AIMS at the end of the six weeks of dosing. Top-line data from this placebo-controlled study is expected in the third quarter of 2013.

Additionally, the Company is conducting appropriate preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome.

The Company anticipates and end-of-phase-II meeting for NBI-98854 in tardive dyskinesia to be held with the FDA in the fourth quarter of 2013.

Conference Call and Webcast Today at 8:00 AM Eastern Time
Neurocrine will hold a live conference call and webcast today at 8:00 a
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 The report ... Chemicals), by Application (Cosmetics & Toiletries, and Soaps & ... to 2019”, has defined and segmented the Fragrance Ingredients ... trends in terms of value. The market has been ... North America, Europe, Asia-Pacific, Latin America, and Rest of ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 2014 ... HCL Industry” is a professional and in-depth research ... provides basic Naltrexone HCL information, including its definition, ... as industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment & ...
(Date:10/30/2014)... 2014 James Sherley says he has been ... stem cell technology since his days as a principal investigator ... the late 1990’s. Sherley founded the ASCTC as a ... all the intellectual property developed in Sherley’s research over the ... Institute of Technology (MIT), and more recently as a senior ...
Breaking Biology Technology:Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4
... Inc. (Nasdaq: NSTK ) announced today that they ... leader in the production of,plasma products, to develop an ... administered by injection to control and prevent,bleeding in patients ... with our new global partner to evaluate the,feasibility of ...
... new, free white paper,addressing the challenges of ... awaiting combination products manufacturers, is now available,for ... combination products are experiencing dramatic growth, the,convergence ... of regulatory,challenges. Manufacturers must ensure their products ...
... Finesse Solutions, LLC,Santa Clara, CA, a manufacturer ... applications, announced the general release of its,TruBio(TM) IOQ ... guesswork,out of validation and to complement the fully ... of control systems can be expensive and time,consuming, ...
Cached Biology Technology:Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding 2Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers 2Finesse Introduces TruBio(TM) IOQ 2
(Date:10/30/2014)... Bacteria in the gastrointestinal tract fulfill many vital ... same bacteria can induce strong inflammatory responses by ... and enter the bloodstream. , Although acute inflammation ... chronic or systemic inflammation is linked to numerous ... involvement of inflammatory processes in the development of ...
(Date:10/30/2014)... 30 October 2014 Biological membranes are mainly composed ... adsorption of solution ions onto lipid membranes helps ... new study provides a quantitative description of the ... Joanna Kotyńska and Zbigniew Figaszewski from the University ... study describing these findings, just published in ...
(Date:10/29/2014)... and gas production are well over recommended levels in ... journal Environmental Health . High levels of benzene, ... the first to be based on community sampling by ... used to supplement official air-quality monitoring programs. , Unconventional ... readily flow to the surface. This is because they ...
Breaking Biology News(10 mins):Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... in Northern Ireland, the number of people surviving the disease ... Each year there are between 50-60 men and women ... have died. The survival rates in Northern Ireland for ... the UK, and its patients are benefiting from improved treatment ...
... In 2012 Wiley-Blackwell, the Scientific, Technical, Medical, and Scholarly ... begin publishing 44 titles new to its journal program, ... collaboration with societies or other organizations. Brand new ... of 2012 include Advanced Healthcare Materials , ...
... 28, 2012) Abstracts are now being accepted for ... Diseases Society of America (IDSA), the Society for Healthcare ... and the Pediatric Infectious Diseases Society (PIDS). ... 2012, in San Diego, CA. With the theme Advancing ...
Cached Biology News:More people surviving cancer in Northern Ireland 2Wiley-Blackwell adds 44 titles to journal publishing program in 2012 2
Request Info...
... Concentration Basement Membrane Extract Cultrex HC20+ ... vivo applications where higher protein concentrations ... strength, and elevated levels of tumor ... of lot-to-lot consistency and controlled protein ...
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
...
Biology Products: